Global Reach Genepharm has established a presence in over 90 countries, highlighting a ready market for certified generics and potential partnerships to expand distribution, licensing, or co-development in new regions.

Production Capacity With dual EU GMP compliant lines and a substantial monthly output across conventional and oncological solids, Genepharm can meet high-volume orders and support market entry strategies for large healthcare systems and distributors.

Therapeutic Coverage Portfolio spans cardiology, diabetes, oncology, urology, and antipsychotics, suggesting opportunities for portfolio expansion, line extensions, and strategic alliances in high-demand therapeutic areas.

Ownership and History Privately owned plant and long-standing industry presence since 1971 position Genepharm as a stable partner for long-term supply agreements, risk-sharing arrangements, and OEM collaborations.

Recent Ownership Change Acquisition by MS Pharma Group in 2019 indicates a potential shift in regional focus and distribution capabilities across Middle East, Turkey, and Africa, creating avenues for regional distribution partnerships and channel expansions.